The treatment backbone for Ph+ ALL is shifting away from intensive chemotherapy like hyper-CVAD. Chemotherapy-free regimens combining blinatumomab with a TKI (preferably ponatinib) are becoming the new standard, showing outcomes that are at least as good as, and likely better than, traditional chemotherapy.

A common assumption that older patients may prefer simpler, continuous medication regimens is often incorrect. Clinical experience shows that the vast majority of patients, regardless of age, are interested in a time-limited therapy option, provided it can be delivered conveniently without infusions.

An expert argues the path to curing metastatic cancer may mirror pediatric ALL's history: combining all highly active drugs upfront. Instead of sequencing treatments after failure, the focus should be on powerful initial regimens that eradicate cancer, even if it means higher initial toxicity.

Combinations of menin inhibitors with standard chemotherapy are achieving impressively high remission rates (e.g., 89% composite remission) in newly diagnosed KMT2A-rearranged AML. This is a significant development, as this genetic subtype has historically been very challenging to treat effectively.

Similar to FLT3 inhibitors like midostaurin, which failed in the relapsed setting but succeeded upfront, menin inhibitors are expected to show dramatically better efficacy when combined with standard induction or HMA/Venetoclax in newly diagnosed patients.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

While adding a menin inhibitor to the azacitidine/venetoclax doublet for older/unfit AML patients increases response rates, it leaves little reserve for marrow function. This can lead to increased risk of early, fatal complications like infection or bleeding, requiring careful dose management.

In oncology R&D, a successful two-drug combination isn't the final goal but the new standard of care to build upon. Researchers immediately begin planning for "triplets"—adding a third agent to the successful doublet—demonstrating a relentless, forward-looking strategy to incrementally improve patient outcomes.

The future standard of care for AML could move towards all-oral triplet therapies. Citing promising data from the SAVE trial, the speaker suggests these better-tolerated, outpatient regimens could replace harsh inpatient chemotherapy for many patients, improving quality of life.